Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
1. 请及时下载文件确认是否正确, 系统将在 2026-07-24 10:58:33 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s1470-2045(26)00193-2
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204526001932
其他信息:
出版社: Elsevier BV
作者: Herui Yao; Qingyuan Zhang; Huiping Li; Yongmei Yin; Shusen Wang; Quchang Ouyang; Tao Sun; Wei Li; Xiaojia Wang; Min Yan; Biyun Wang; Jing Cheng; Zhongsheng Tong; Wei Wei; Xinshuai Wang; Weimin Xie; Zhengkui Sun; Peng Yuan; Cuizhi Geng; Lu Gan; Xinghua Han; Wenfeng Li; Shoubing Zhou; Xi Yan; Jinnan Gao; Tienan Yi; Jingna Wu; Zhaofeng Niu; Fangmeng Fu; Jianyun Nie; Yongsheng Wang; Bing Zhao; Zhiyong Wu; Zhengqiu Zhu; Yaping Yang; Jianli Zhao; Zhen Sheng; Ying Zhang; Lin Cheng; Xiaoyu Zhu; Erwei Song
